About AVT
Browse Articles
Authors
Customer Services

Commentary

SARS-CoV-2 and HIV protease inhibitors: why lopinavir/ritonavir will not work for COVID-19 infection

Elise J Smolders, Lindsey HM te Brake, David M Burger

Corresponding author name: Elise J Smolders
Corresponding author e-mail: Elise.Smolders@radboudumc.nl

doi: 10.3851/IMP3365

Abstract

Since the beginning of the outbreak of severe acute respiratory syndrome (SARS) coronavirus (CoV) 2 lopinavir/ritonavir was selected for treatment. The recent publication of Cao et al in the NEJM[1] showed that lopinavir/ritonavir treatment did not accelerate clinical improvement compared with standard of care. This raised the question if we in retrospect could have known this. The aim of this paper is to gather all the available evidence and to comprehensively discuss this issue.

<< BACK

Copyright © 2020 Nucleus Holdings Ltd. Part of Nucleus Global.
Design and Technology by Nucleus Global
Company registration No. 321 0712 (England & Wales). Registered Office address: Admiral House 76-78 Old Street, London EC1V 9AZ.